Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
12.11 USD -0.41% Intraday chart for Viridian Therapeutics, Inc. -9.96% -44.40%
May. 16 Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
May. 09 Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating MT

Evolution of the average Target Price on Viridian Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

84969b719a.qQRR_XB4TLKcP5WsE3w_JG-kbEfGgHlAiCNotP9eKBc.wVMJijtIdfnEZePCKjlJZV_cLnST1SAY40sp4bssdyH-djufGh0q3tJ7xA~ab3155cc0fefdab4f2c67dd1a96f5bae

Analyst Recommendations on Viridian Therapeutics, Inc.

Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25 MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating MT
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating MT
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating MT
Oppenheimer Raises Viridian Therapeutics Price Target to $36 From $35, Maintains Outperform Rating MT
Wedbush Raises Viridian Therapeutics' PT to $40 From $37, Keeps Outperform Rating; Says Remains Among a Top Pick Into 2024 MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $38 From $42, Maintains Market Outperform Rating MT
B. Riley Lowers Viridian Therapeutics' PT to $29 From $46 to Reflect Dilutive Financing, Lower Peak Sales in TED; Maintains Buy Rating MT
RBC Cuts Price Target on Viridian Therapeutics to $35 From $44, Keeps Outperform Rating, Speculative Risk Qualifier MT
Wedbush Lowers Viridian Therapeutics' PT to $37 From $46 on Heels of Leadership Changes, Private Placement; Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Viridian Therapeutics to $37 From $40, Keeps Buy Rating MT
Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $35 From $40, Maintains Outperform Rating MT
Wells Fargo Adjusts Price Target on Viridian Therapeutics to $39 From $46, Maintains Overweight Rating MT
Wedbush Lifts Viridian Therapeutics' PT to $46 From $45 After Adjusting Share Count Assumptions, Keeps Outperform Rating MT
Wedbush Adjusts Viridian Therapeutics' PT to $45 From $48 After Reporting Results For Phase 1/2 Trial for Chronic Thyroid Eye Disease Treatment, Keeps Outperform Rating MT
BTIG Research Initiates Coverage on Viridian Therapeutics With Buy Rating, $46 Price Target MT
RBC Initiates Viridian Therapeutics at Outperform With Speculative Risk, Sets Price Target at $44, Sees 'Best Second-Mover Advantage' in Thyroid Eye Disease MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $44 From $46, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $40 From $45, Maintains Outperform Rating MT
Wedbush Lifts Viridian Therapeutics' Price Target to $48 From $46, Keeps Outperform Rating MT
Viridian Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.11 USD
Average target price
36.5 USD
Spread / Average Target
+201.40%
High Price Target
46 USD
Spread / Highest target
+279.85%
Low Price Target
20 USD
Spread / Lowest Target
+65.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viridian Therapeutics, Inc.

Oppenheimer
B. Riley
Wedbush
JMP Securities
RBC Capital Markets
HC Wainwright
Needham & Co.
Wells Fargo Securities
BTIG
Stifel Nicolaus
SVB Securities LLC
Credit Suisse
Evercore ISI
SVB Leerink
Ladenburg Thalmann

Ratings for Viridian Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. Consensus Viridian Therapeutics, Inc.